CNS drug delivery systems: Novel approaches

Recent Patents on Drug Delivery and Formulation

Volumn 3, Issue 1, 2009, Pages 71-89

  Pathan, Shadab A ^a   Iqbal, Zeenat ^a   Zaidi, Syed M A ^b   Talegaonkar, Sushma ^a   Vohora, Divya ^a   Jain, Gaurav K ^a   Azeem, Adnan ^a   Jain, Nitin ^a   Lalani, Jigar R ^c   Khar, Roop K ^a   Ahmad, Farhan J ^a,b  

^a HAMDARD UNIVERSITY   (India)

^b HAMDARD UNIVERSITY   (India)

^c M S UNIVERSITY OF BARODA   (India)

Author keywords

BBB; CNS; Drug targeting; Liposomes; Nanoparticles; Patents; Polymers

Indexed keywords

AMBISONE; AMPHOTERICIN B; CARMUSTINE; CLOTRIMAZOLE; DIAZEPAM; DOXORUBICIN; FOLIC ACID; GALANTAMINE; HALOPERIDOL; HUPERZINE A; LIPOSOME; LORAZEPAM; MANNITOL; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NANOPARTICLE; NICOTINIC RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; POLOXAMER; POLYPEPTIDE; PREDNISOLONE; QUINOLONE DERIVATIVE; SEDATIVE AGENT; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; VALPROIC ACID; ZOLPIDEM; DRUG;

ALZHEIMER DISEASE; ANTIGEN BINDING; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BRAIN; BRAIN TUMOR; CELL MEMBRANE; CELL TRANSFORMATION; CENTRAL NERVOUS SYSTEM; DRUG ADMINISTRATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG TARGETING; ENCEPHALITIS; EPILEPSY; GLIOBLASTOMA; HUMAN; HUNTINGTON CHOREA; IMPLANT; INFECTION; INSOMNIA; INVASIVE PROCEDURE; LIPOPHILICITY; MICELLE; MICROEMULSION; MIGRAINE; MOLECULAR WEIGHT; MULTIPLE SCLEROSIS; NON INVASIVE PROCEDURE; OSMOSIS; PARKINSON DISEASE; PATENT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SENILE DEMENTIA; WITHDRAWAL SYNDROME; CENTRAL NERVOUS SYSTEM DISEASE; DRUG DESIGN; METABOLISM; METHODOLOGY; PHARMACEUTICS; TRANSPORT AT THE CELLULAR LEVEL; UNITED STATES;

BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PATENTS AS TOPIC; PHARMACEUTICAL PREPARATIONS; TECHNOLOGY, PHARMACEUTICAL; UNITED STATES;

EID: 60849089627     PISSN: 18722113     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221109787158355     Document Type: Review

References (205)

1. Pardridge WM. Why is the global CNS pharmaceutical market so under-penetrated? Drug Discov Today 2002; 7(1): 5-7.
2. Ricci M, Blasi P, Giovagnoli S, Rossi C. Delivering drugs to the central nervous system: a medicinal chemistry or a pharmaceutical technology issue? Curr Med Chem 2006; 13: 1757-1775.
3. Banks WA, Kastin AJ. Delivering peptides to the central nervous system: Dilemmas and strategies. Pharm Res 1991; 8: 1345-1350.
4. Cornford, EM. The blood-brain barrier, a dynamic regulatory interface. Mol Physiol 1985; 7: 219-260.
5. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharm Rev 2005; 57: 173-185.
6. Edwards RT. Drug delivery via the blood-brain barrier. Nat Neurosci 2001; 4: 221-222.
7. Pardridge WM. Blood-brain barrier drug targeting: The future of brain drug development. Mol Interv 2003; 3: 90-105.
8. Brightman M. Ultrastructure of brain endothelium, Physiology and pharmacology of the blood-brain barrier. In: Bradbury MWB, Eds. Handbook of experimental pharmacology. Springer-Verlag Berlin 1992; Vol. 103: pp. 1-22.
9. Schlossauer B, Steuer H. Comparative anatomy, physiology and in vitro models of the blood-brain and blood-retina barrier. Curr Med Chem 2002; 2: 175-186.
10. Nabeshima S, Reese TS, Landis DM, Brightman MW. Junctions in the meninges and marginal glia. J Comp Neurol 1975; 164(2): 127-169.
11. Crone C. The blood-brain barrier: a modified tight epithelium, The Blood-Brain Barrier in Health and Disease. In: Suckling AJ, Rumsby MG, Bradbury MWB, Eds. Ellis Harwood. Chichester 1986; pp. 17-40.
12. Levin VA. Relationship of octanol/water partition and molecular weight to rat brain capillary permeability. J Med Chem 1980; 23: 682-684.
13. Habgood MD, Begley DJ, Abbott NJ. Determinants of passive drug entry into the central nervous system. Cell Mol Neurobiol 2000; 20: 231-225.
14. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989; 58: 137-171.
15. Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at bloodbrain barrier sites. Proc Natl Acad Sci USA1989; 86: 695-698.
16. Pardridge W. Transport of small molecules through the blood-brain barrier: biology and methodology. Adv Drug Deliv Rev 1995; 15: 5-36.
17. Reddy JS, Venkateswarlu V. Novel delivery systems for drug targeting to the brain. Drugs Future 2004; 29: 63-69.
18. Kabanov AV, Batrakova EV. New technologies for drug delivery across the blood brain barrier. Curr Pharm Des 2004; 10: 1355-1363.
19. Misra A, Ganesh S, Shahiwala A, Shah SP. Drug delivery to the central nervous system: a review. J Pharm Pharm Sci 2003; 6(2): 252-273.
20. Abbott NJ, Romero IA. Transporting therapeutics across the bloodbrain barrier. Mol Med Today 1996; 2: 106-113.
21. Bodor NS, Kaminski JJ. Prodrugs and site-specific chemical delivery systems. Annu Rep Med Chem 1987; 22: 303-313.
22. Han HK, Amidon GL. Targeted prodrug design to optimize drug delivery. AAPS Pharm Sci 2000; 2: E6.
23. Wu J, Yoon SH, Wu WM, Bodor NS. Synthesis and biological evaluation of a brain targeted chemical delivery system of [Nva2]-TRH. J Pharm Pharmacol 2002; 54: 945-950.
24. Higuchi, T., Bodor, N. S., Shek, E.: US3929813 (1975).
25. Higuchi, T., Bodor, N. S., Shek, E.: US3962447 (1976).
26. Bodor, N.S.: US4540564 (1985).
27. Bodor, N.S.: US4888427 (1989).
28. Bodor, N.S.: US5017566 (1991).
29. Loftsson, T.: US5324718 (1994).
30. Yaksh, T. L., Hill, H.F.: US5180716 (1993).
31. Katz, R., Tomoaia-Cotisel, M.: US20066005004 (2006).
32. Christian, S.T.: US20060189547A1 (2006).
33. Atlas, D., Melamed, E., Offen, D.: US20060211628 A1 (2006).
34. Chung, S., Jeon, O.Y., Kumar, K., Yu, S. H.: US20060280796A1 (2006).
35. Lipshutz, B.H.: US20070203080A1 (2007).
36. Bergley DJ. The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system. J Pharm Pharmacol 1996; 48: 136-146.
37. Pardridge WM. Receptor-mediated peptide transport through the blood-brain barrier. Endocrine Rev 1986; 7: 314-330.
38. Demeule, M., Beliveau, R.: MXPA05007322 (2002).
39. Walus LR, Pardridge WM, Starzyk RM, Friden PM. Enhanced uptake of rsCD4 across the rodent and primate blood-brain barrier following conjugation to anti- transferring receptor antibodies. J Pharmacol Exp Ther 1996; 277: 1067-1075.
40. Pardridge WM, Kang YS, Buciak JL, Yang J. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid trans-cytosis through the blood-brain barrier in vivo in the primate. Pharm Res 1995; 12: 807-816.
41. Shusta, E.V., Wang, X.X., Cho, Y.P.: WO2007143711 (2007).
42. Starr, C.M., Zankel, T., Gabathuler, R.: CA2525236 (2005).
43. Neuwelt, E.A.: US5124146 (1991).
44. Wu D, Yang J, Pardridge WM. Drug targeting of a peptide radio pharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. J Clin Invest 1997; 100(7): 1804-1812.
45. Abulrob, A., Zhang, J.: WO2007036022 (2007).
46. Tchistiakova, L., Li, S., Pietrzynski, G., Alakhov, V.: WO0190139 (2001).
47. Beliveau, R., Che, C., Regina, A., Demeule, M.: CA2597958 (2002).
48. Beliveau, R.: US20060182684A1 (2006).
49. Beliveau, R., Demeule, M., Che, C., Regina, A.: US20060189515A1 (2006).
50. Mueller, R., Lueck, M., Kreuter, J.: DE19745950 (1999).
51. Pardridge, W.M.: US4801575 (1989).
52. Pardridge, W.M.: US20026372250 (2002).
53. Pardridge, W.M., Boado, R. J.: US20016287792 (2001).
54. Pardridge, W.M.: US2005142141 (2005).
55. Forni, F., Vandelli, M.A., Constantino, L.: EP1819723(2007).
56. Hochman, S.: WO2005094497 (2005).
57. Ferguson, I.A.: US2003083299 (2003).
58. Kozarich, J.W., Musso, G.F., Malfroy-Camine, B.: KR100242597 ((2001).
59. Daneman, R., Barres, B.: WO2007137303 (2007).
60. Pardridge, W.M.: US4801575 (1989).
61. Pardridge, W.M., Schimmel, P.R.: US4902505 (1990).
62. Fukuta, M., Iinuma, S., Okada, H.: US5442043 (1995).
63. Bentley, M.D., Roberts, M.J.: US20030139346A1 (2003).
64. Friden, P.M.: US5833988 (1998).
65. Pardridge WM, Wu D, Sakane T. Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration. Pharm Res 1998; 15(4): 576-582.
66. Temsamani, J., Rees, A.R.: US20060293242A1 (2006).
67. Temsamani, J., Christophe, R., Rees, A.R.: WO03026700A2 (2003).
68. Nelson, T., Quattrone, A., Alkon, D.: US20070264351 (2007).
69. Garcia-Garcia E, Andrieux K, Gil S, Couvreur P. Colloidal carriers and blood-brain barrier (BBB) translocation: A way to deliver drugs to the brain? Int J Pharm 2005; 298: 274-292.
70. Peracchia MT, Vauthier C, Desmaele D, et al. Pegylated nanoparticles from a novel methoxypolyethylene glycol cyano acrylatehexadecyl cyanoacrylate amphiphilic copolymer. Pharm Res1998; 15: 550-556.
71. Peracchia MT, Fattal E, DesmaeleD, et al. Stealth PEGylated polycyanoacrylatnanoparticles for intravenous administration and splenic targeting. J Control Release 1999; 60: 121-128.
72. Peracchia MT, Harnisch S, Pinto AH, et al. Visualization of in vitro protein rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles. Biomaterials 1999; 20: 1269-1275.
73. Adams ML, Lavasanifar A, Kwon GS. Amphiphilic block copolymers for drug delivery. J Pharm Sci 2003; 92: 1343-1355.
74. Jones M, Leroux J. Polymeric micelles-a new generation of colloidal drug carriers. Eur J Pharm Biopharm 1999; 48: 101-111.
75. Allen C, Maysinger D, Eisenberg A. Nano-engineering block copolymer aggregates for drug delivery. Colloids Surf B Biointerfaces 1999; 16: 3-27.
76. Kabanov AV, Batrakova EV, Melik-Nubarov NS, et al. New classes of drug carries: micelles of poly(oxyethylene) - poly(oxypropylene block copolymersas microcontainers for drug targeting form blood in brain. J Control Release 1992; 22: 141-158.
77. Batrakova EV, Li S, Vinogradov SV, Alakhov VY, Miller DW, Kabanov AV. Mechanism of pluronic effect on Pglycoprotein efflux system in blood brain barrier: contributions of energy depletion and membrane fluidization. J Pharmacol Exp Ther 2001; 299: 483-493.
78. Batrakova EV, Miller DW, Li S, Alakhov VY, Kabanov AV, Elmquist WF. Pluronic P85 enhances the deliveryof digoxin to the brain:in vitro and in vivo studies. J Pharmacol Exp Ther 2001; 296: 551-557.
79. Alakhov V, Klinski E, Li S, et al. Block copolymer-based formulation of doxorubicin from cell screen to clinical trials. Colloids Surf B Biointerfaces 1999; 16: 113-134.
80. Witt KA, Huber JD, Egleton RD, Davis TP. Pluronic p85 block copolymer enhances opioid peptide analgesia. J Pharmacol Exp Ther 2002; 303: 760-767.
81. Ringe, K., Radunz, H.: WO2006056362 (2006).
82. Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle technology for drug delivery across the blood brain barrier. Drug Dev Ind Pharm 2002; 28: 1-13.
83. Calvo P, Gouritin B, Chacun H, et al. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res 2001; 18: 1157-1166.
84. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Del Rev 2001; 47: 65-81.
85. Ramge P, Unger RE, Oltrogge JB, Begley D, Von Briesen H, Kreuter J. Polysorbate 80-coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human, bovine and murine primary brain capillary endothelial cells. Eur J Neuro 2000; 12: 1935-1940.
86. Olivier JC. Drug targeting to brain with targted nanoparticles. NeuroRx 2005; 2: 108-119.
87. Heppe, K., Heppe,A., Schliebs, R.: US2006051423 (2006).
88. Chen, J.W.: CN1850032 (2006).
89. Sabel, B.A., Walz, C., Ringe, K.: WO2004017945 (2004).
90. Kreuter, J., Gelperina S, Maksimenko, O., Khalanskiy, A.: WO2007110152 (2007).
91. Kreuter, J., Alyautdin, R.N., Karkevich D.A., Sabel, B.A.: US20006117454 (2000).
92. Gasco, M.R.: US20026419949 (2002).
93. Dennis, D.M., Martin, C.R., Rogers, R.J., Stewart, J.D.: US20077195780 (2007).
94. Sabel, B.A., Schroeder, U.: US20020034474A1 (2002).
95. Gustow E., Ryde, T., Cooper, E.R.: WO2004078162(2004).
96. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000; 50: 161-177.
97. Mehnert W, Mäder K. Solid lipid nanoparticles - production, characterization and applications. Adv Drug Deliv Rev 2001; 47: 165-196.
98. Göppert TM, Müller RH. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: Comparison of plasma protein adsorption patterns. J Drug Target 2005; 13(3): 179-87.
99. Shastri, V.P., Sussman, E., Jayagopal, A.: WO2006044660 (2006).
100. Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 1996; 93: 14164-14169.
101. Micklus, M.J., Greig, N.H., Rapoport, S.I.: US20020025313A1 (2002).
102. Chen, Y.L.: CN1833633 (2006).
103. Pardrige, W.M.: WO01182900A1 (2001).
104. Pardrige, W.M., Huwyler, J.: WO022092A1 (1998).
105. Omori N, Maruyama K, Jin G, et al. Targeting of post-ischemic cerebral endothelium in rat by liposomes bearing polyethylene glycol-coupled transferrin. Neurol Res 2003; 25: 275-279.
106. Schmidt J, Metselaar JM, Gold R. Intravenous liposomal prednisolone downregulates in situ TNF-alpha production by Tcells in experimental autoimmune encephalomyelitis. J Histochem Cytochem 2003; 51: 1241-1244.
107. Koukourakis MI, Koukouraki S, Giatromanolaki A, et al. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas-rationale for combination with radiotherapy. Acta Oncol 2000; 39: 207-211.
108. Hau P, Fabel K, Baumgart U, et al. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 2004; 100: 1199-1207.
109. Yoshida J, Mizuno M. Clinical gene therapy for brain tumors liposomal delivery of anticancer molecule to glioma. J Neurooncol 2003; 65: 261-267.
110. Sugawa N, Ueda S, Nakagawa Y, et al. An antisense EGFR oligonucleotide enveloped in Lipofectin induces growth inhibition in human malignant gliomas in vitro. J Neuro-Oncol 1998; 39: 237-244.
111. Roney C, Kulkarni P, Arora V, et al. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J Control Release 2005; 108: 193-214.
112. Grieg NH. Optimizing drug delivery to brain tumors. Cancer Treat Rev 1987; 14: 1-28.
113. Wang PP, Frazier J, Brem H. Local drug delivery to the brain. Adv Drug Deliv Rev 2002; 54: 987-1013.
114. Langer R. Polymer implants for drug delivery in the brain. J Control Release 1991; 16: 53- 60.
115. Tamargo RJ, Sills AKJ, Reinhard CS, Pinn ML, Long DM, Brem H. Interstitial delivery of dexamethasone in the brain for the reduction of peritumoral edema. J Neurosurg 1991; 74: 956-961.
116. Tamargo RJ, Myseros JS, Epstein JI, Yang MB, Chasin M, Brem H. Interstitial chemotherapy of the 9L gliosarcoma: Controlled release polymers for drug delivery in the brain. Cancer Res 1993; 53: 329-333.
117. Brem H, Walter K, Langer R. Polymers as controlled drug delivery devices for the treatment of malignant brain tumors. Eur J Pharm Biopharm 1993; 27: 2-7.
118. Brem H, Langer R. Polymer-based drug delivery to the brain. Sci Med 1996; 3(4): 52-61.
119. Wang J, Wang BM, Schwendeman SP. Characterization of the initial burst release of a model peptide from poly(d,l-lactide-coglycolide) micro-spheres. J Control Release 2002; 82: 289-307.
120. Neuwelt EA. Implication of the blood-brain barrier and its manipulation. Plenum Press NY 1989; pp. 1-2.
121. Miller G. Breaking down barriers. Science 2002; 297: 1116-1118.
122. Kroll RA, Neuwelt EA. Outwitting the blood brain barrier for therapeutic purposes: Osmotic opening and other means. Neurosurgery 1998; 42: 1083-1099.
123. Rapoport SI. Osmotic opening of blood-brain barrier: Principles, mechanism and therapeutic applications. Cell Mol Neurobiol 2000; 20: 217-230.
124. Jolesz, F.A., Hynynen K.: WO009807367 (1998).
125. Naito, A.T.: WO03028633 (2003).
126. Matsukado K, Inamura T, Nakano S, Fukui M, Bartus RT, Black KL. Enhanced tumor uptake of carboplatin and survival in gliomabearing rats by intracarotid infusion of the bradykinin analog, RMP-7. Neurosurgery 1996; 39: 125-133.
127. Krewson CE, Klarman ML, Saltzman WM. Distribution of nerve growth factor following direct delivery to brain interstitium. Brain Res 1995; 680: 196-206.
128. Shalev, A.: WO2004043334 (2004).
129. Shalev, A., Gross, Y.: WO0185094 (2001).
130. Jolesz, F.A., Hynynen, K.: US5752515 (1998).
131. Ansarinia, M.M.: US20026405079 (2002).
132. Miller, L., Meythaler, J., Peduzzi, J.: EP1600186 (2005).
133. Tobinick, E.L.: US200600945 (2006).
134. Gilbert, S.J.: US20070055214A1 (2007).
135. Laske, D.W., Oldfield, E.H., Bobo, R.H., Dedrick, R.L., Morrison, P.F.: US5720720 (1998).
136. Kucharczyk, J., Truwit, C. L.: US20036537232 (2003).
137. Putz, D.A.: US20077241283 (2007).
138. Menei P, Benoit JP, Boisdron-Celle M, Fournier D, Mercier P, Guy G. Drug targeting into the central nervous system by stereotactic implantation of biodegradable microspheres. Neurosurgery 1994; 34: 1058-1064.
139. Mittal S, Cohen A, Maysinger D. In vitro effects of brain derived neurotrophic factor released from microspheres. NeuroReport 1994; 5: 2577-2582.
140. Benoit JP, Faisant N, Venier-Julienne MC, Menei P. Development of microspheres for neurological disorders: From basics to clinical applications. J Control Release 2000; 65: 285-296.
141. Yang MB, Tamargo RJ, Brem H. Controlled delivery of 1, 3-bis(2-chloroethyl)-1-nitrosourea from ethylene-vinyl acetate copolymer. Cancer Res 1989; 49: 5103-5107.
142. Grossman SA, Reinhard C, Colvin OM, et al. The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J Neurosurg 1992; 76: 640-647.
143. Ewend MG, Williams JA, Tabassi K, et al. Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models. Cancer Res 1996; 56: 5217-5223.
144. Brem H, Ewend MG, Piantadosi S, Greenhoot J, Burger PC, Sisti M. The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. J Neurooncol 1995; 26: 111-123.
145. Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 1997; 41: 44-49.
146. Roullin VG, Deverre JR, Lemaire L, et al. Anti-cancer drug diffusion within living rat brain tissue: an experimental study using [3H] (6)-5-fluorouracil-loaded PLGA microspheres. Eur J Pharm Biopharm 2002; 53: 293-299.
147. Amanda M-D, Stephan HD, David WM, Thomas RT. Implantable microencapsulated dopamine (DA): A new approach for slow-release DA delivery into brain tissue. Neurosci Lett (Ireland) 1988; 92(3): 303-309.
148. Sabel, B.A., Freese, A., Saltzman, W.M.: US4883666 (1989).
149. Boer GJ, Tjitske PV-W, Jenneke K, Joop V-H. Successful ventricular application of the miniaturized controlled-delivery Accurel technique for sustained enhancement of cerebrospinal fluid peptide levels in the rat. J Neurosci Methods 1984; 11: 281-289.
150. Nathalie, F., Benoit, J.-P., Philippe, M.: US20046803052 (2004).
151. Sabel, B.A. Freese, A., Saltzman, W.M., During, M.J.: US5601835 (1997).
152. Brem, H., Langer, R.S., Domb, A.J.: US5651986 (1997).
153. Frey, II, W.H.: US5624898 (1997).
154. Frey, II, W.H.: WO00033813A1 (2000).
155. Gizurarson, S.: WO09901229A1 (1999).
156. Cevc, G.: WO20044350A1 (2004).
157. Mattern, C., Hacker, R.: US5756071 (1998).
158. Parnell, F.W.: CA2560798 (2007).
159. Wu, F., Zhao, Y., Wang, Z.: CN1579407 (2005).
160. Frey, W.H.: US5624898 (1997).
161. Frey, II, W.H., Thorne, R., Gary, C.X.: W000033813 (2000).
162. Frey, II, W.H.: WO07947A1 (1991).
163. Frey, II, W.H.: US20016180603 (2001).
164. Frey, II, W.H.: EP0504263B1 (1997).
165. Frey, II, W.H.: US20030215398A1 (2003).
166. Frey, II, W.H.: US20020072498A1 (2002).
167. Frey, II, W.H.: US20016313093 (2001).
168. Frey, II, W.H.: US20026342478 (2002).
169. Frey, II, W.H.: US20026407061 (2002).
170. Xiao, L.L., Xu, B., Luo, J., Johnson, K., Frey, II, W.H., Tozzo, E., Duhl, D.: US20030229025A1 (2003).
171. Xiao, L.L., Xu, B., Luo, J., Johnson, K., Frey II, W.H., Tozzo, E., Duhl, D.: US20070004743A1 (2007).
172. Xiao, L.L., Xu, B., Luo, J., Johnson, K., Frey, II, W.H., Tozzo, E., Duhl, D.: WO03072056A2 (2003).
173. Houdi, A.A.: US20006121289 (2000).
174. Hussain, A.A., Dittert, L.W., Traboulsi, A.: US20026369058 (2002).
175. Quay, S.C., Costantino, H.R., Houston, M.E. JR; Leoard, A.K.: US20060003989A1 (2006).
176. Heller, J., Frazer, N., Tsui Collins, A.L.: US20060141029A1 (2006).
177. Heller, J., Frazier, N., Chang, C.-C., Lin, E., Huang, R.C.C.: US20060141047A1 (2006).
178. Huang, R.C.C., Park, R., Chang, C.-C., Liang, Y.-C., Mold, D.L., Elaine, H.J., Frazer, N.: US20060141025A1 (2006).
179. Meyerson, L.R., Went, G.T., Fultz, T.J.: US20050245617A1 (2005).
180. Went, G.T., Fultz, T.J.: US20060252788A1 (2006).
181. Meyerson, L.R., Went, G.T., Fultz, T.J., Burkoth, T.S.: US20060240043A1 (2006).
182. Levin, B. H.: US20050281751A1 (2005).
183. Hussain, A.A., Dittert, L.W., Qaisi, A.M., Traboulsi, A.: US20036380175 (2003).
184. Cummings, C.J., Shapiro, G., Sankrithi, N.S., Chesworth, R.: US20070037800A1 (2007).
185. Tao, T., Gu, Y., Yue, P.: CN1621039 (2005).
186. Frey, II, W.H., Thorne, R., Gary, C.X.: WO000033814 (2000).
187. Frey, II, W.H.: WO00033813A1 (2000).
188. Frey, II, W.H.: US20030072793 (2003).
189. Frey, II, W.H.: EP1137401B1 (2005).
190. Frenkel, D., Maron, R., Burt, D., Weiner, H.L.: US20060229233A1 (2006).
191. Choi, Y.M., Kim, K.H.: US20050002987A1 (2005).
192. Choi, Y.M., Kim, K.H.: WO04110403A1 (2004).
193. Ambikanandan, M., Tushar, K.V.: 1061/MUM/2004 (2005).
194. Ambikanandan, M., Tushar, K.V.: 1124/MUM/2004 (2005).
195. Ambikanandan, M., Tushar, K.V.: 1125/MUM/2004 (2005).
196. Solomon, B.: US20060034855A1 (2006).
197. Wermeling, D.P.: US20016610271 (2001).
198. Wermeling, D.P.: US20010055571A1 (2001).
199. Castile, J.D., Cheng, Y.H., Jenkins, P.G., Smith, A., Watts, P.J.: US20070140981A1 (2007).
200. Muhammad, A.: US20077241283 (2007).
201. Eriksson, U., Lawrence, D., Su, E. J., Strickland, D., Yepes, M., Fredriksson L.: US20070265203A1 (2007).
202. Lerner, E.N.: US20020183683A1 (2002).
203. Lerner, E.N., Lerner, L.: US20030191426A1 (2003).
204. LeBowitz, J.: US20060121018A1 (2006).
205. Lamensdorf, I., Katzhendler, J.: US20060142227A1 (2006).